Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?

Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?

Item
http://www.wikidata.org/entity/Q45753417
Application of human factors engineering (HFE) to the design of a naloxone auto-injector for the treatment of opioid emergencies.International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database.Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal.Opiate addiction and overdose: experiences, attitudes, and appetite for community naloxone provision.Take-home naloxone treatment for opioid emergencies: a comparison of routes of administration and associated delivery systems.Characteristics of persons who inject drugs and who witness opioid overdoses in Vietnam: a cross-sectional analysis to inform future overdose prevention programs.President's message: Food and Drug Administration approved naloxone and continued use of improvised nasal naloxone: What is a treatment advocate and educator to do?Intranasal naloxone and related strategies for opioid overdose intervention by nonmedical personnel: a review.Intranasal naloxone soon to become part of evolving clinical practice around opioid overdose prevention.Ensure global access to naloxone for opioid overdose management.Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose.Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study.Managing opioid overdose in pregnancy with take-home naloxone.Comments on Strang et al. (2016): 'Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?'.Radical red tape reduction by government supported nasal naloxone: the Norwegian pilot project is innovative, safe and an important contribution to further development and dissemination of take-home naloxone.Pharmacokinetics of a new, nasal formulation of naloxone.Ethical issues and stakeholders matter.
P2860

Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?

Item
http://www.wikidata.org/entity/Q45753417
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Clinical provision of improvis ...... f essential safety procedures?
@en
Clinical provision of improvis ...... f essential safety procedures?
@nl
type
label
Clinical provision of improvis ...... f essential safety procedures?
@en
Clinical provision of improvis ...... f essential safety procedures?
@nl
prefLabel
Clinical provision of improvis ...... f essential safety procedures?
@en
Clinical provision of improvis ...... f essential safety procedures?
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
Clinical provision of improvis ...... f essential safety procedures?
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698